Cholangiocarcinoma and Primary Sclerosing Cholangitis

17 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Udhayvir Singh Grewal, MD, a Senior Medical Oncology Fellow in the Division of Hematology, Oncology, and Blood and Marrow Transplantation at the University of Iowa Hospitals and Clinics in Iowa City, IA, reviews his article appearing in the August 2025, issue of Mayo Clinic Proceedings, where using large retrospective analysis highlighting key patient-level risk factors for cholangiocarcinoma in primary sclerosing cholangitis he found patients with early-stage disease in the primary sclerosing cholangitis + intrahepatic cholangiocarcinoma cohort who underwent liver transplantation had significantly higher mortality than intrahepatic cholangiocarcinoma only patients. However, he did not note a statistically significant mortality difference between the two groups for patients that underwent hepatic resection and received adjuvant capecitabine. Dr. Grewal also found patients that underwent liver transplantation had significantly better overall survival than patients who underwent hepatic resection with adjuvant capecitabine Available at: https://mayocl.in/4ejERf6
Categoria
Oncology
Commenta per primo questo video.

Prossimo